Lowe launches 12 medical marijuana products

Canada LegalCanada Global News USALowe launches 12 medical marijuana products
27
Jul
2018

Jamaican scientist Dr Henry Lowe yesterday launched 12 cannabis-based nutraceutical products manufactured by his company, Medicanja Limited, and made an appeal for regional collaboration in the growth and utilisation of medicinal cannabis.

“If we truly believe in regional cooperation and wish to work with each other on the matter of medicinal cannabis, then… the time has come for us to use the achievements of Medicanja to bring a new type of regional collaboration, based on an enlightened technical cooperation and trade through the use of our products and services in Caricom,” Lowe said at the launch held at his Eden Gardens Wellness Resort and Spa on Lady Musgrave Road, St Andrew.

The scientist, known for his anti-cancer research and the use of Jamaican plants in the development of nutraceutical products, proposed that the cooperation could be achieved “through the provision of education, training and a variety of technical services to enable the public and private sectors in Caricom to understand, grow and utilise medicinal cannabis for their therapeutic and commercial purposes”.

The products launched yesterday, and which have been approved by the Ministry of Health, include CanjaRub, CanjaCol, Relevium Cream, Relevium Spray, Somnican (One Drop) Orals, and Tivasat all of which are designed to treat various forms of pain; CBD Oil Sublingual Drops, designed to relieve symptoms related to nausea and inflammation; I-Cann, a supplement to assist people diagnosed with open angle glaucoma, normal tension glaucoma, and increased intra-ocular pressure; Epilec Pro, oral drops for epilepsy; Sclorican, an oral spray for neuropathic pain, spasticity, muscle spasms and sleep disturbances caused by multiple sclerosis; Cannrepel anti-itch mosquito repellent spray; and Oromuccosol Spray.

Health Minister Dr Christopher Tufton, in his remarks, said the development of the products demonstrated Medicanja’s commitment and “the advancement of an industry that, even though it has been around for a very long while, still has to be considered [as being] in its relatively infant stage”.

“From a public health perspective, we are with you and we are with those who are committed to taking this particular approach. We want to be as accommodating as possible, because we do have a responsibility also, in public health, to advance solutions to the public health concerns of our people,” he said.

Tufton said that the public health sector acknowledges the benefits of medicinal marijuana, adding that “we have seen enough to be convinced that there is significant potential”.

Lowe said that his company was confident in the safety of its products and he expects that they will be approved by the healthcare authorities regionally and globally.

He stated that Medicanja’s achievements over the last four-and-a-half years have been “nothing less than phenomenal”, adding that the basic scientific research and development, clinical research studies, formulation and product development have been achieved in a relatively short time, while meeting the required quality standards.

“The launch of these 12 products today is a landmark to the rest of the region and world, where we have demonstrated that little Jamaica can use science and technology and innovation to create a variety of health care products,” Lowe said.

To read more visit: http://www.jamaicaobserver.com/news/lowe-launches-12-medical-marijuana-products-moots-regional-collaboration_139789?profile=1373

Post your comments here

Your email address will not be published. Required fields are marked *